SEC Form 4 · accession 0001209191-19-009885
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fletcher Payne
Officer — Chief Financial Officer
Period of report
Feb 11, 2019
Accepted (ET)
Feb 13, 2019 · 7:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 11, 2019 | A | 1,002 | $7.04 | A | 3,731 | D | |
| Common StockF2 | holding | — | — | — | 501 | I | By Charles and Nancy Payne 2000 Trust | |
| Common Stock | holding | — | — | — | 666 | I | By iRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 11, 2019.
- F2A Section 16 exempt transaction was completed.